U.S. Biotech Stock News

NYSE:PFS
NYSE:PFSBanks

Top Dividend Stocks To Consider In April 2026

The United States market has experienced a robust performance, rising 3.4% over the last week and 30% over the past year, with earnings projected to grow by 16% annually. In this thriving environment, dividend stocks that offer reliable income and potential for growth can be particularly appealing to investors seeking stability amidst market gains.
NYSE:BEN
NYSE:BENCapital Markets

Franklin Resources (BEN) Valuation Check After Recent Share Price Momentum And Digital Asset Initiatives

Franklin Resources stock overview after recent performance Franklin Resources (BEN) has seen mixed share performance recently, with a 0.6% gain over the past day, a 7.0% rise over the past week, and small declines over the past month and past 3 months. See our latest analysis for Franklin Resources. At a share price of $25.04, recent trading shows short term momentum building after a strong 7 day share price return, while the 1 year total shareholder return of 49.4% points to a much stronger...
NYSE:GHC
NYSE:GHCConsumer Services

Assessing Graham Holdings (GHC) Valuation After New SWE Education Partnership

PPI, a Kaplan subsidiary under Graham Holdings (GHC), has been chosen as the exclusive licensure prep partner for the Society of Women Engineers. This provides investors with a fresh data point on the company’s professional education footprint. See our latest analysis for Graham Holdings. The recent education partnerships come against a backdrop of steady recent momentum, with a 7 day share price return of 3.68% and a 1 year total shareholder return of 22.14%, supported by a 3 year total...
NYSE:PNC
NYSE:PNCBanks

Is PNC Financial (PNC) Still Attractive After A 52% One-Year Share Price Surge?

If you are wondering whether PNC Financial Services Group at US$223.23 is offering fair value or a stretched price, the next sections will walk through the key numbers that matter for you. The stock has returned 5.4% over the past week, 8.2% over the last 30 days, 5.6% year to date and 52.1% over the past year, which puts recent moves front and center for anyone thinking about valuation and risk. Recent headlines around PNC Financial Services Group have focused on its position among large US...
NYSE:NOW
NYSE:NOWSoftware

ServiceNow (NOW) Valuation Check After Broad AI Platform Overhaul And Recent Share Price Weakness

ServiceNow (NOW) just rolled out a major AI overhaul, turning every product into an AI-enabled service with built-in data connectivity, workflow automation, security, and governance that ships as part of the standard package. See our latest analysis for ServiceNow. Despite the AI overhaul and a steady flow of new partnerships, ServiceNow’s 1-day share price return of 7.86% decline and 30-day share price return of 22.98% decline sit alongside a 1-year total shareholder return of 42.69% loss...
NYSE:BV
NYSE:BVCommercial Services

BrightView Holdings (BV) Valuation Check As Recent Returns Soften And Narratives Diverge

Recent performance snapshot BrightView Holdings (BV) has traded around $11.80 recently, with the stock showing mixed returns, including a small fall over the past month and a larger decline over the past 3 months. Over a longer horizon, BrightView’s total return figures are varied, including a loss across the past 5 years but a very large gain across the past 3 years, which may catch your eye if you compare different holding periods. See our latest analysis for BrightView Holdings. At around...
NYSE:EW
NYSE:EWMedical Equipment

Should EVOQUE’s New TRISCEND II Data Shift the Long-Term Thesis for Edwards Lifesciences (EW) Investors?

Edwards Lifesciences recently reported new two-year TRISCEND II data at ACC.26 showing its EVOQUE transcatheter tricuspid valve replacement system nearly eliminated tricuspid regurgitation, improved quality of life, and was associated with lower all-cause mortality without added device-related risk in severe tricuspid regurgitation patients. This growing body of evidence, now spanning randomized trials and real-world registry data in more than 1,000 patients across the US and Europe,...
NasdaqGS:IRTC
NasdaqGS:IRTCMedical Equipment

A Look At iRhythm Holdings (IRTC) Valuation After New ACC 2026 Clinical And AI Announcements

iRhythm Holdings (IRTC) is back in focus after a busy presence at the American College of Cardiology 2026 meetings, where it shared new Zio clinical data, AI partnerships, and education and accessibility initiatives. See our latest analysis for iRhythm Holdings. The share price has retreated in recent months, with a 90 day share price return of a 34.15% decline and a year to date share price return of a 32.56% decline, even as the 1 year total shareholder return sits at 19.61%. This suggests...
NYSE:BE
NYSE:BEElectrical

US Stock Market Today: S&P 500 Futures Edge Lower As Energy Inflation Jitters Build

The Morning Bull - US Market Morning Update Friday, Apr, 10 2026 US stock futures are slightly softer this morning, with key contracts for the S&P 500 and Nasdaq 100 edging down by around 0.1%, as investors focus on inflation and energy. Markets are bracing for US March inflation at about 3.3%, with headline consumer prices expected to rise 0.9% month on month, largely tied to higher energy costs from the Iran war, which keeps the cost of living uncomfortably high. At the same time, the...
NYSE:IVZ
NYSE:IVZCapital Markets

Is Invesco (IVZ) Still Attractive After A 93% One Year Share Price Surge

If you are wondering whether Invesco's current share price reflects its true worth, the recent moves in the stock make the valuation story especially important to understand. The share price closed at US$23.57, with returns of 93.3% over 1 year, 63.2% over 3 years and 8.3% over 5 years. Year to date it is down 12.5%, with a 7 day return of a 2.4% decline and a 30 day return of a 1.7% decline. Recent coverage has focused on how asset managers are responding to shifts in investor preferences...
NasdaqGS:GILT
NasdaqGS:GILTCommunications

A Look At Gilat Satellite Networks (NasdaqGS:GILT) Valuation After New U.S. Army DataPath Orders

Why the new U.S. Army orders matter for Gilat Satellite Networks (GILT) Gilat Satellite Networks (NasdaqGS:GILT) just reported about US$6 million in new orders for its Gilat DataPath unit, extending field and technical services that support U.S. Army global communications over the next six months. The award continues a multi year engagement under the GTACS II contract. It signals ongoing demand from a large defense customer and gives investors another reference point when thinking about...
NasdaqGS:PANW
NasdaqGS:PANWSoftware

Palo Alto Networks Joins Project Glasswing Raising AI Security Investment Questions

Palo Alto Networks has joined Project Glasswing as a founding partner, helping launch an industry wide initiative built on Anthropic's Claude Mythos2 Preview AI model. The collaboration focuses on proactively securing global software infrastructure and addressing AI driven cyber threats across critical systems. The development positions Palo Alto Networks as a core participant in a collective defense effort that goes beyond typical product announcements. Palo Alto Networks (NasdaqGS:PANW)...
NYSE:HD
NYSE:HDSpecialty Retail

Home Depot (HD) Is Up 5.6% After ESG Push Meets Easing Oil Costs and Tech Investment Shift

In early April 2026, Home Depot faced a cluster of shareholder proposals on board leadership structure, plastics and biodiversity reporting, data privacy, employee healthcare, charitable giving, and packaging recyclability, while also putting to a vote amendments to its Certificate of Incorporation, including officer exculpation, at its May 21, 2026 annual meeting. At the same time, Home Depot’s governance and ESG debates unfolded against a backdrop of easing oil-linked cost pressures and...
NasdaqGS:CG
NasdaqGS:CGCapital Markets

How CTAC’s Redemption Surge And Withdrawal Limits At Carlyle Group (CG) Has Changed Its Investment Story

Carlyle Group’s Carlyle Tactical Private Credit Fund recently restricted investor withdrawals to its standard 5% quarterly limit after experiencing redemption requests equal to roughly three times that threshold in the first quarter. This redemption surge and resulting withdrawal cap draw attention to liquidity management in private credit vehicles and add another layer of scrutiny to Carlyle’s broader business as it prepares to report upcoming quarterly results. We’ll now examine how CTAC’s...
NasdaqGS:JJSF
NasdaqGS:JJSFFood

A Look At J&J Snack Foods (JJSF) Valuation As Dippin’ Dots Enter Grocery Freezer Aisles

Dippin’ Dots expansion puts J&J Snack Foods in focus Dippin’ Dots’ move into grocery freezer aisles gives J&J Snack Foods (JJSF) a fresh retail growth angle, expanding beyond theme parks and theaters and putting more attention on how this rollout aligns with the company’s current valuation. See our latest analysis for J&J Snack Foods. Despite the excitement around Dippin’ Dots entering grocery freezers, J&J Snack Foods’ share price tells a more cautious story. The 1-day share price return is...
NYSE:AXP
NYSE:AXPConsumer Finance

Assessing American Express (AXP) Valuation After Recent Share Price Pullback And Strong Multi Year Returns

Event context and recent performance snapshot American Express (AXP) is back in focus after recent trading that left the shares at $317.77, with a one-month return of 4.8% and a decline of 15.4% over the past three months. See our latest analysis for American Express. For context, this recent pullback comes after a strong run, with the 1-year total shareholder return at 30.1% and the 3-year total shareholder return at 102.9%, while shorter term share price momentum has cooled. If this kind of...
NasdaqGS:RARE
NasdaqGS:RAREBiotechs

Ultragenyx Pharmaceutical (RARE) Is Up 6.5% After FDA Accepts UX111 BLA Resubmission for Review

Ultragenyx Pharmaceutical recently reported that the FDA has accepted for review its resubmitted BLA for UX111, an AAV9 gene therapy for Sanfilippo syndrome Type A (MPS IIIA), with a PDUFA action date set for September 19, 2026. The filing includes up to eight years of follow-up data suggesting durable clinical and biomarker effects in a disease with no approved treatments, highlighting UX111’s potential importance for a small but severely affected patient population. With UX111 now under...